Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Merus from a buy rating to a hold rating in a research note on Saturday, August 10th. Roth Capital initiated coverage on shares of Merus in a research report on Friday, June 28th. They set a buy rating and a $20.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Merus presently has an average rating of Buy and an average price target of $22.57.
NASDAQ MRUS opened at $15.77 on Wednesday. Merus has a 12 month low of $11.00 and a 12 month high of $22.40. The company’s 50 day moving average is $15.76 and its two-hundred day moving average is $14.14.
Merus (NASDAQ:MRUS) last released its earnings results on Thursday, May 30th. The biotechnology company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.22. Merus had a negative net margin of 104.10% and a negative return on equity of 41.68%. The company had revenue of $8.75 million for the quarter, compared to analysts’ expectations of $7.47 million. As a group, analysts expect that Merus will post -1.73 earnings per share for the current year.
Institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in shares of Merus by 18.8% during the fourth quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 2,373 shares during the last quarter. Morgan Stanley raised its position in shares of Merus by 3.1% during the second quarter. Morgan Stanley now owns 92,776 shares of the biotechnology company’s stock valued at $1,359,000 after buying an additional 2,788 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Merus by 63.5% during the second quarter. JPMorgan Chase & Co. now owns 8,722 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 3,389 shares during the last quarter. Athanor Capital LP bought a new stake in shares of Merus during the second quarter valued at approximately $334,000. Finally, Artal Group S.A. raised its position in shares of Merus by 16.7% during the second quarter. Artal Group S.A. now owns 350,000 shares of the biotechnology company’s stock valued at $5,128,000 after buying an additional 50,000 shares during the last quarter. Hedge funds and other institutional investors own 52.39% of the company’s stock.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Further Reading: How mutual funds make money
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.